Phase II study of a moderate-intensity preparative regimen with allogeneic peripheral blood stem cell transplantation for hematologic diseases: The Texas transplant consortium experience

Biology of Blood and Marrow Transplantation

Volumn 8, Issue 8, 2002, Pages 420-428

  Shaughnessy, P J ^a   Ornstein, D ^a   Ririe, D ^a   Callander, N ^a   Anderson, J E ^a   Pollack, M S ^a   Freytes, C O ^a   Cruz, J ^a   Rodriquez, T ^a   Bachier, C ^a   LeMaistre, C F ^a  

^a TEXAS TRANSPLANT INSTITUTE   (United States)

Author keywords

Allogeneic stem cell transplantation; Graft versus malignancy; Reduced intensity preparative regimen; Regimen related toxicity

Indexed keywords

ACICLOVIR; BUSULFAN; CD34 ANTIGEN; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOSPORIN A; FLUCONAZOLE; FLUDARABINE; GANCICLOVIR; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; PENTAMIDINE; PHENYTOIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; THYMOCYTE ANTIBODY;

ADULT; AGE; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOTRANSPLANTATION; CHIMERA; CLINICAL ARTICLE; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG FATALITY; EXPERIENCE; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC DISEASE; HEMATOPOIETIC SYSTEM; HLA MATCHING; HUMAN; INFECTION; INFECTION RISK; LUNG TOXICITY; LYMPHOCYTE COUNT; LYMPHOCYTE TRANSFER; MALE; MORBIDITY; MORTALITY; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; PHASE 2 CLINICAL TRIAL; SEIZURE; SERUM SICKNESS; SIBLING; STEM CELL TRANSPLANTATION; SURVIVAL TIME; ALLOTRANSPLANTATION; GRAFT SURVIVAL; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; ISOGRAFT; METHODOLOGY; MICROBIOLOGY; MIDDLE AGED; MULTICENTER STUDY; OPPORTUNISTIC INFECTION; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HEMATOLOGIC DISEASES; HUMANS; MALE; MIDDLE AGED; OPPORTUNISTIC INFECTIONS; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TRANSPLANTATION, ISOGENEIC;

EID: 0036377523     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1053/bbmt.2002.v8.pm12234167     Document Type: Article

References (45)

1. The development of the scientific foundation of hematopoietic cell transplantation based on animal and human studies
2. Increasing utilization of allogeneic bone marrow transplantation. Results of the 1988-1990 survey
3. Retrospective evaluation of autologous bone marrow transplantation vs. allogeneic bone marrow transplantation from HLA identical related donor in acute myelocytic leukemia. A study of the EBMT
4. Treatment of CML by marrow transplantation
5. Prognostic factors of patients with acute myeloid leukemia allografted in first complete remission: An analysis of the EORTC GIMEMA AML 8A Trial
6. Bone marrow transplantation in patients aged 45 years and older
7. Allogeneic bone marrow transplantation in patients who relapse after autologous transplantation
8. Second allogeneic transplantation after failure of first autologous transplantation
9. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts
10. Influence of acute and chronic graft versus host disease on relapse and survival after bone marrow transplantation from HLA identical siblings as treatment of acute and chronic leukemia
11. Graft versus leukemia reactions after bone marrow transplantation
12. The graft versus leukemia phenomenon: Is GVL separable from GVHD?
13. Graft versus leukemia effect of donor lymphocyte transfusions in marrow grafted patients
14. Cellular mediated immunotherapy of leukemia in conjunction with autologous and allogeneic bone marrow transplantation in experimental animals and man
15. Graft versus leukemia effect of donor buffy coat transfusions on recurrent leukemia after marrow transplantation
16. Allogenic cell therapy for relapsed leukemia following bone marrow transplantation with donor peripheral blood lymphocytes
17. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse post allogeneic bone marrow transplantation
18. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation
19. Donor leukocyte infusions for multiple myeloma
20. Graft versus myeloma effect: Proof of principle
21. Allogeneic bone marrow transplantation in multiple myeloma. European group for bone marrow transplantation
22. Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: A retrospective case matched study from the European group for blood and marrow transplantation
23. Allogeneic bone marrow transplantation for lymphoma
24. Regression of metastatic renal cell carcinoma after nonmyeloablative allogeneic peripheral blood stem cell transplantation
25. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases
26. Engraftment of allogeneic hematopoietic progenitor cells with purine analog containing chemotherapy: Harnessing graft versus leukemia without myeloablative therapy
27. Transplant-lite: Induction of graft versus malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor cell transplantation as treatment for lymphoid malignancies
28. Lymphohematopoietic engraftment in minimally myeloablated hosts
29. Rapid achievement of complete donor chimerism and low regimen related toxicity after reduced conditioning with fludarabine, carmustine, melphalan, and allogeneic transplantation
30. High rate of secondary viral and bacterial infections in patients undergoing allogeneic bone marrow mini-transplantation
31. Non-myeloablative allogeneic transplantation ("microallograft") for refactory myeloma after two preceding autografts: Feasibility and efficacy in a patient with active aspergillosis
32. Allogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin's disease
33. Reduction in the frequency of transplant-related complications in patients with chronic myeloid leukemia undergoing BMT preconditioned with a new, non-myeloablative drug combination
34. Dose-reduced conditioning for allogeneic blood stem cell transplantation: Durable engraftment without antithymocyte globulin
35. Fludarabine-based nonmyeloablative chemotherapy followed by infusion of HLA-identical stem cells for relapsed leukemia and lymphoma
36. Hematopoietic stem cell allografts using a non-myeloablative conditioning regimen can be safely performed on an outpatient basis: Report of four cases
37. Mixed lymphohaemopoietic chimerism and graft versus lymphoma effects after non-myeloablative therapy and HLA mismatched bone marrow transplantation
38. Molecular remission of chronic myeloid leukaemia following a non myeloablative allogeneic peripheral blood stem cell transplant: In vivo and in vitro evidence for a graft versus leukaemia effect
39. Allogeneic stem cell transplantation in a patient with refractory Burkitt's lymphoma using non-myeloablative conditioning regimen
40. Melphalan and purine analog-containing preparative regimens: Reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation
41. Hematopoietic cell transplantation in older patients with hematologic malignancies: Replacing high-dose cytotoxic therapy with graft-versus-tumor effects
42. Clinical manifestations of graft versus host disease in human recipients of marrow from HLA matched sibling donors
43. Chronic graft versus host disease syndrome in man; a long term clinical pathologic study of 20 Seattle patients
44. The syndrome of hepatic veno-occlusive disease after marrow transplantation
45. Nonparametric estimation from incomplete observations